Table 2.

Standardized occurrence rates (95 % confidence intervals) of serious hypoglycemia per 1,000 person-years of follow-up, by exposure group—overall and stratified by average daily dose

	Overall	Low dose	High dose
glyburide	68.0 (64.9, 71.2)	64.5 (60.8, 68.2)	74.3 (67.1, 81.4)
glimepiride	52.9 (48.9, 56.9)	50.3 (45.2, 55.4)	58.8 (50.3, 67.2)
glipizide	49.6 (47.2, 51.9)	42.5 (39.6, 45.4)	59.4 (55.1, 63.8)
repaglinide	44.4 (34.7, 54.1)	37.2 (27.8, 46.7)	66.8 (33.8, 99.9)
nateglinide	23.2 (15.6, 30.7)	19.1 (8.9, 29.3)	28.2 (15.7, 40.7)
rosiglitazone	14.6 (12.3, 17)	14.5 (11.7, 17.4)	17.2 (11.7, 22.8)
pioglitazone	13.8 (11.9, 15.7)	8.5 (6.3, 10.7)	18.1 (14.8, 21.4)
metformin	11.9 (11.3, 12.5)	8.8 (7.9, 9.7)	13.4 (12.6, 14.3)